Brief: Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results And Provides An Update On Clinical Development Programs
09/08/2021 21:07
Aug 9 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2021
FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT
PROGRAMS
* Q2 NON-GAAP LOSS PER SHARE $1.32
* Q2 GAAP LOSS PER SHARE $2.00
* Q2 EARNINGS PER SHARE ESTIMATE $-2.06 -- REFINITIV IBES
DATA
* REAFFIRMS CASH RUNWAY THROUGH MID-2024
* REAFFIRM OUR PLAN TO SUBMIT A MAA WITH EMA IN Q4 OF 2021
FOR
MARKETING APPROVAL OF BARDOXOLONE FOR TREATMENT OF CKD
Source text for Eikon: ID:nBw4CtGHKa
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer